Meeder Asset Management’s 89bio ETNB Stock Holding History

Meeder Asset Management’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-229	Closed	-$5K	–	1979
2020 Q3	$5K	Buy	+229	New	+$7.26K	﹤0.01%	1565

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Meeder Asset Management's ETNB Position: Q4 2020 in Review

Meeder Asset Management sold out of 89bio (ETNB) in Q4 2020, closing a stake of 229 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in ETNB in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 68 funds tracked by Wall St. Rank hold ETNB as of Q4 2020.

Meeder Asset Management reported no remaining 89bio position as of Q4 2020 after selling out during the quarter.
Meeder Asset Management sold 229 89bio shares in Q4 2020, an estimated $5K.
Meeder Asset Management first reported a position in 89bio in Q3 2020 and held it in 1 quarter.
Meeder Asset Management's 89bio position peaked at $5K in Q3 2020.
68 funds tracked by Wall St. Rank held 89bio as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.